BLUDIGO
Drug
Provepharm Inc.
Total Payments
$960,270
Transactions
224
Doctors
135
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $721,378 | 153 | 102 |
| 2023 | $178,771 | 59 | 32 |
| 2022 | $60,121 | 12 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $743,675 | 62 | 77.4% |
| Consulting Fee | $200,471 | 33 | 20.9% |
| Honoraria | $9,000 | 9 | 0.9% |
| Travel and Lodging | $3,851 | 3 | 0.4% |
| Entertainment | $1,954 | 102 | 0.2% |
| Food and Beverage | $1,294 | 11 | 0.1% |
| Education | $26.40 | 4 | 0.0% |
Payments by Type
Research
$743,675
62 transactions
General
$216,595
162 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PVP-22IC04 and PVP-22IC05 | Provepharm Inc. | $635,163 | 3 |
| PVP-22IC04 | Provepharm Inc. | $66,258 | 1 |
| PVP-22IC05 | Provepharm Inc. | $30,625 | 1 |
| PVP-22IC03 | Provepharm Inc. | $6,975 | 1 |
| 4300-1 | Provepharm Inc. | $2,275 | 1 |
| PVP-24BD01 | Provepharm Inc. | $1,479 | 0 |
| PVP-IC1901 | Provepharm Inc. | $900.00 | 0 |
Top Doctors Receiving Payments for BLUDIGO — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA-C | Physician Assistant | Dover, DE | $15.33 | 1 |
| , DO | Obstetrics & Gynecology | Newark, DE | $15.33 | 1 |
| , MD | Urology | Goodyear, AZ | $15.29 | 1 |
| , CRNP | Women's Health | Horsham, PA | $14.48 | 1 |
| , M.D | Obstetrics & Gynecology | Philadelphia, PA | $14.48 | 1 |
| , M.D | Urology | Dallas, TX | $14.11 | 1 |
| , M.D | Urology | Dallas, TX | $14.11 | 1 |
| , MD | Urology | Dallas, TX | $14.11 | 1 |
| , MD | Urology | Meadville, PA | $13.36 | 1 |
| , M.D.,F.A.C.O.G | Obstetrics & Gynecology | Holmdel, NJ | $13.15 | 1 |
| , M.D | Urology | Oklahoma City, OK | $13.14 | 1 |
Ad
Manufacturing Companies
- Provepharm Inc. $960,270
Product Information
- Type Drug
- Total Payments $960,270
- Total Doctors 135
- Transactions 224
About BLUDIGO
BLUDIGO is a drug associated with $960,270 in payments to 135 healthcare providers, recorded across 224 transactions in the CMS Open Payments database. The primary manufacturer is Provepharm Inc..
Payment data is available from 2022 to 2024. In 2024, $721,378 was paid across 153 transactions to 102 doctors.
The most common payment nature for BLUDIGO is "Unspecified" ($743,675, 77.4% of total).
BLUDIGO is associated with 7 research studies, including "PVP-22IC04 and PVP-22IC05" ($635,163).